Androgenetic Alopecia Therapies Master List Pipeline 2024
This article contains a complete list and description of every known biotech and med-tech company working on a clinical therapy for hair loss prevention/hair growth from all phases spanning research to late-stage clinical trials in 2024.
Over the past several years, the amount of new hair growth related technologies in development have multiplied like never before in recent decades. This article will allow us to keep track of the multitude of potential therapies being developed, and differs from the well known Ultimate Guide to Hair Regeneration article which only lists the most prominent, furthest developed, or most discussed therapies in the industry. This Master List will list every known clinical therapy regardless of how early or obscure they are thought to be.
Biotech Companies Working On Hair Growth Treatments
AddPharma – Two therapies sit in this Korean biotech’s pipeline for the treatment of hair loss, AD-208 and AD-106. AD-208 is simply a modified dosage of dutasteride, while the more interesting AD-106 is an undisclosed repurposed drug. AD-106 is currently at the phase 1 stage. There has been no news on the progress of this research in 2024.
Almirall – Finjuve is the brand name topical finasteride drug from the Barcelona-based pharmaceutical company Almirall. Typically, this would not have made the list since topical finasteride is widely available from multiple telemedicine companies in the US, however, some of our European readers have vouched for the importance of this formula in their countries. Finjuve, also known as ALM12845 and P-3074, has completed a phase 3 clinical trial and is apparently ready to be marketed at any moment.
Amplifica – Amplifica was founded by well-known hair researcher Dr. Maksim Plikus of UC Irvine and hair transplant surgeon Dr. William Rassman in 2020. Amplifica posted results for its first-in-human trial for AMP-303 in September 2024. The company has two other treatments in the pre-clinical stage. AMP-203 (osteopontin – This treatment is based on proteins which are found in hairy moles, aka hairy nevi), and AMP-601 (aka SCUBE3).
Aneira Pharma – ANR-001 is a combination topical drug formula intended to regrow hair. It apparently comprises minoxidil and latanoprost. Aneira has shared some impressive photos on their website and mention that along with regrowth their formula tends to add pigment to patients’ hair. A fundraising press release also mentioned Aneira plans to create other hair growth products in the future, including but not limited to a version of ANR-001 for eyebrow growth. We could not find any news on this in 2024.
Applied Biology – AB-101 is a microbiome based topical therapy intended to break down scalp DHT. Another way of describing the technology is “DHT-eating bacteria.” This project is still in the early stages of R&D. The website domain is available and we could not find any progress on this in 2024.
Aranda Pharma – ADA-308 is a topical androgen receptor inhibitor. Aranda Pharma is based in Finland and is developing therapies for acne and androgenic alopecia. Both of their programs are listed at the preclinical stage. In August 2024 an article was published showing that ADA-308 showed potent antiandrogen activity in prostate cancer models.
BiologicsMD – PTH-CBD is a pharmaceutical protein being developed for hair growth and bone disorders. In 2016, the company announced potential therapies for AGA, AA, and chemotherapy-induced alopecia. Over the past 5 years, BiologicsMD has seemingly not made any announcements of progress.
Biosplice Therapeutics – SM04554 is a small molecule Wnt agonist. In previous clinical trials, it showed the ability to create the formation of new hair follicles, however, its overall hair growth (aesthetic) effects were found to be marginal. Biosplice has completed a phase 3 trial with SM04554 without releasing the data and has told potential patients that it has ceased its own development of the drug and will explore licensing SM04554 to another company.
Caregen – This Korean biotech is a world leader in peptide development. While Caregen has been known to produce cosmeceuticals and mesotherapy kits related to hair health, their pipeline now shows a pharmaceutical treatment for hair loss which is listed at the preclinical safety stage.
Carmell Therapeutics – CT-401 is a plasma-based bioactive material (PBM) which will be used in combination with a microneedling device to create hair growth. The company states that this therapy “utilizes microneedling (radio frequency) to create micro channels in the scalp and then massages Carmell’s proprietary sticky liquid paste into the scalp where the material will reside for days and weeks, constantly bathing the area with growth factors and other regenerative factors.” It functions in a way as “off the shelf” PRP. This therapy is listed at the preclinical stage on Carmell’s website.
CarthroniX – RCGD423 is a molecule that has shown the ability to stimulate hair follicle stem cells via lactate production in preclinical studies. CathroniX has recently shown this molecule in their pipeline under the development name CX-01 as a hair growth treatment. Recently, this candidate was removed from their pipeline, however, CarthroniX co-founder Ben Van Handel PhD has verified that the company remains pursuant to hair growth therapies while incorporating “additional chemistries.”
CK Regeon – KY19382 is a small molecule activator of the Wnt/Beta-catenin pathways. It is also an analog of the PTD-DBM peptide which became popular following a research paper detailing hair follicle neogenesis in 2017. KY19382 is also listed as the project code CKH-T-5108 on the CK Regeon website and is preparing to enter clinical trials. As of November 2024, we could not find CKH-T-5108 in their pipeline.
Cosmo Pharmaceuticals – Breezula is a topical androgen receptor-antagonist that has completed phase 2 trials for AGA in males. A 24-weekRCT was conducted, with results published in 2022 showing that application 3 times daily increased total hair counts without side effects observed.
Cure Bio TX – CBT2004 is peptide that mimics a specific function of the AIMP1 protein. Cure Bio has completed preclinical testing of the peptide on human hair follicles in a dish and a patch model of human dermal papilla cells in vivo. A toxicity study was also successfully completed. An IND application for clinical testing may come in 2022. As of November 2024, we could find no updates for this potential treatment.
Daewoong Pharma/Inventage Lab – IVL3001 is an innovative microsphere-encapsulated form of finasteride which can be delivered through injection. These injections provide slow-release, long lasting doses of finasteride which can treat a patient from 1-3 months depending on dose and concentration. Daewoong Pharma received approval to begin a phase 1 trial of IVL3001 in Australia in September 2021.
Dermaliq – DLQ01 is a topical drug, likely to be latanoprost, which incorporates a proprietary delivery system called hyliQ. In July 2024, Dermaliq announced results from their Phase 1b/2a trial for AGA, with a non-significant increase in total area hair count from the baseline. The treatment was also well-tolerated.
dNovo – Reprogrammed hair follicle stem cells are the therapeutic focus of dNovo. The company unveiled itself in January 2022 and announced a team of researchers from Harvard and Stanford were responsible for starting dNovo. It was also announced in January 2022 that dNovo has raised $2.7M in seed funding.
Eirion Therapeutics – ET-02 and ET-03 are small molecule topical and oral drugs for androgenic alopecia and hair greying reversal treatment. Both program lines are based on the same small molecule PAI-1 inhibitor. Both programs are at the preclinical stage.
Epibiotech – EPI-001 is the lead dermal papilla cell therapy candidate, from Epibiotech. The company runs an expansive R&D program for hair growth research and has multiple other therapeutic candidates, including a PGD2 inhibitor and a Ripk1 inhibitor. Epibiotech is one of the premier hair R&D companies in the world. In may 2024, Epibiotech’s trial “Phase 1/2a clinical trial to evaluate the safety/tolerance and explore the efficacy of EPI-001 for patients with androgenetic alopecia,” has been selected by the Korean Fund for Regenerative Medicine (KFRM) as a new project.
Exicure – This Chicago-based biotech wields some very impressive spherical nucleic acid technology for the treatment of various conditions. In 2019, Exicure received a $25M investment from Allergan (now acquired by Abbvie) to develop advanced therapies for hair loss disorders. A program update is expected in 2022. In November 2024, the company was found to not have sufficient cash to continue to fund operations. They have agreed to sell shares to HiTron Systems Inc.
Follica – FOL-004 is a combinational therapy involving a proprietary microneedling device and topical minoxidil. Potentially more interesting is CWL08006, a Wnt activating molecule made by JW Pharma, which Follica has entered a collaborative research agreement for as of 2017. In 2024 – the website has had all information removed, and we don’t know if they are continuing research.
Fukuda Lab – Large scale production of human hair follicle germs is the research focus of the Junji Fukuda PhD and his colleagues at Yokohama National University. The method developed by Fukuda seeks to create a solution for the labor-intensive task of creating thousands of hair follicle germs by utilizing specific biomaterial beads and 3D bioprinting. Fukuda told Follicle Thought in 2018 that he had began collaborations with larger companies at that time and hoped to begin clinical trials around 2023. There has been no news about this research in 2024.
HairCell – Bioelectric stimulation sent through electrodes into the scalp is what makes up the HairCell technology. The company uses patented bioelectric signals to upregulate various proteins such as IGF-1, VEGF, klotho, sonic hedgehog, and many more for the purpose of regrowing hair. A small human study is planned to begin in late 2021 in the US.
HairClone – Multiplied dermal papilla cell injections are the lead program at this UK based biotech. HairClone also offers a hair follicle banking and cryopreservation service for patients. The company is slated to begin offering multiplied dermal papilla cells to a limited group of physicians in the UK for treatments in 2022. In August 2024, HairClone was awarded an Innovate UK grant to explore hair growth stimulants in partnership with Cell Research Therapeutics.
Haplnscience – HS-301 is a hair growth therapy which targets the HAPLN1 protein. CEO Hakbae Choi has told Follicle Thought that the company plans to begin a clinical trial in Korea in 2023. As of 2024, HS-301 was still in the preclinical stage.
Han Bio – A therapy involving dermal papilla cell injections is the main hair growth candidate from Han Bio. The company has also talked about developing hair care products involving growth factors in the Korean media. Han Bio also stated that it could begin a preclinical trial of its dermal papilla therapy in November 2021 in collaboration with fellow Korean company DTNC. A clinical trial of the cell therapy is planned for H1 2022.
Hope Medicine – HMI-115 is a PRL receptor antibody therapy for the treatment of male and female pattern baldness. The drug has completed promising preclinical trials in the stump-tailed macaques species and has completed a phase 1 human trial showing safety in Europe. Hope Medicine plans to initiate multi-center phase 2 clinical trials for HMI-115 in 2022. In January 2024, positive outcomes were reported from a Phase 1b study in Australia treating 12 men with androgenic alopecia.
Inscobee – A micro-encapsulation containing stem cells which secretes cytokines into the scalp is the therapeutic device created by Inscobee. The device acts as an implant which releases beneficial secretions from stem cells into the scalp over time. The core technology was developed by a company called Theracyte. Inscobee is using the Theracyte device in a hair growth setting. Inscobee’s pipeline page lists its hair growth therapy at the preclinical stage.
Insilico Medicine – Peter Diamandis MD, a famous medical, financial, and space exploration entrepreneur shared through his personal blog in 2020 that the AI drug discovery company Insilico Medicine has a tailored molecule for hair growth in its pipeline. It is possible that this project is being done in collaboration with Taisho Pharmaceutical who has been publicly mentioned to be working with Insilico on other projects. As of 2024, there have been no additions to the pipeline for hair loss.
JW Pharmaceutical – JW0061 is a Wnt signaling pathway activating drug developed by J2 Pharmaceutical. it is currently in the pre-clinical stage. In May 2024, JW Pharma presented results showing the efficacy of JW0061 in hair formation and growth in skin organoids.
Kintor Pharmaceutical – KX-826 and GT20029 are two types of anti-androgen receptor molecules being developed by Kintor. GT20029 is considered to be a more advanced type of molecule, called an androgen receptor degrader which uses PROTAC technology. KX-826 is expected to enter a phase 3 clinical trial in China in 2022 and GT20029 is currently undergoing a phase 1 trial in China. In 2024, KX-826 received approval to be sold as a cosmetic under the brand KOSHINE 826. Kintor Pharma has also announced enrollment for its new phase 2/3 trial for AGA and an update of a previous Phase 3 trial. In April 2024, a Phase 2 trial was completed for GT20029 for patients with AGA, finding good safety and tolerability and a statistically significant increase in hairs over the placebo.
Koehler Lab – The Boston-based researcher Dr. Karl Koehler is the inventor of one of the most promising technologies for growing human hair follicles in the lab to date. In July 2021, Dr. Koehler shared with Follicle Thought that his lab has identified an industry partner to help further this technology in a clinical direction. The lab also performs hair growth-promoting drug screens for molecules on its human tissue.
Life Code AI – Artificial intelligence-designed molecules or combination therapies is the therapeutic focus of Life Code AI. The company is based in Hong Kong and currently operates with a reputable team of scientists and executives.
MalliaBioTech – A proprietary, soluble form of the CD83 molecule is the proposed hair growth treatment of this German biotech. In October 2021, it was announced that a research team from the University of Erlangen received the prestigious m4 award along with 500k euros to develop their hair growth therapy. In a youtube video, Prof. Steinkasserer says a human trial take several years to begin. As of November 2024, there have been no updates.
Moogene Medi – This represents the first known CRISPR / Cas9 therapy for androgenetic alopecia in development. Moogene incorporates ultrasound to deliver microbubble-nanoliposomal sgRNA into human hair follicles to suppress the gene known to cause hair loss. The company is currently at the preclinical stage.
OliX Pharmaceuticals – OLX104C is a topical siRNA therapy that acts as an anti-androgen. CEO Dr. Dong Ki Lee stated in a press release from February 2021 that the company plans to initiate a clinical trial for OLX104C by the end of 2022. A Phase 1 clinical trial is underway in Australia (2024).
Omega Therapeutics – An mRNA-encoded epigenetic medicine designed to suppress the SFRP1 gene is the target of Omega Therapeutics. Omega represents another new advanced therapeutic involving RNA to prevent hair loss and create hair growth. Up until now, not much has been disclosed about this therapy program by the publicly traded company. The SFRP1 therapy is currently listed at the preclinical stage on the Omega pipeline page.
Pelage Pharmaceuticals – Small molecules which target hair follicle stem cell metabolism via lactate production are the therapeutic focus of Pelage, likely to be analogs of UK5099. The company is a UCLA spinout based on the research of William Lowry PhD and others. Allergan has also entered an agreement to acquire all of the assets of Pelage Pharmaceuticals. In August 2024, Pelage Pharma announced that the first patients had been doses in its Phase 2a clinical trial evaluating the safety of PP405 for AGA in men and women.
Poietis – This leader in 3D/4D printing technology has engaged with L’Oreal to create a method of bioprinting human hair follicles. This ambitious research collaboration was first announced in 2016, it’s hopeful that the companies will share a formal update in 2022. As of 2024 – no update has been released.
Quark Pharmaceuticals – Topical silencing-RNA therapies for AGA and chemotherapy-induced alopecia are listed in the long term pipeline of Quark Pharmaceuticals. The Quark website also has mentioned a research collaboration with the Suzhou Ribo Life Science company of China for the alopecia related therapies in the past. As of 2024 – no new updates have been released.
Rise Technology – A small pulse generator contained in a baseball cap which delivers low-energy electrical stimulation to the scalp is the product candidate from Rise Technologies. The device was invented by UW Madison researcher Prof. Xudong Wang. Clinical trials may potentially be initiated in 2022 for the device.
Replicel (Shiseido) – RCH-01 is an injectable therapy comprising multiplied dermal sheath cells sourced from hair follicles. The therapy will likely work best in areas which still have some remaining hair growth. Shiseido, who licensed the RCH-01 technology from Replicel for use in Japan, have completed a clinical trial involving a single dose of RCH-01 and are currently engaged in a second trial which involves multiple injections per patient. Results from the multiple injection trial could be shared in late 2022 or 2023. In August 2024, Replicel entered into a definitive agreement for the sale of company assets after facing difficulties commercializing its products and securing funding.
Stemson Therapeutics – The creation of de novo aka “cloned” hair follicles using iPSCs is the primary focus of Stemson. This company stands as the current frontrunner in the USA to bring hair cloning therapy to market if successful. Right now, Stemson is working on perfecting the creation of a human hair follicle using stem cells and testing human skin environment models in animal studies. In March 2024, Stemson and Aderans signed an exclusive hair regeneration licensing deal.
TechnoDerma Medicines – TDM-105795 is a new topical small molecule candidate for hair growth. The drug has entered a phase 1 clinical trial in the USA as of May 2021 and in October 2021 the trial was still recruiting new participants. In February 2024, Technoderma Medicines completed a Phase 2a clinical trial.
TissUse – The neopapillae or “smart hair transplant” technology is a hair multiplication therapy created by the German biotechnology company TissUse. The entirety of the method is not disclosed, but it involves extracting a sample number of hair follicles from a patient and manipulating certain cells from those follicles in petri dishes to create a cell therapy which is intended to create brand new hair follicles. In 2019 a license was given to the Japanese company J Hewitt for the purpose of conducting a clinical trial. That trial or other trials conducted by partners of TissUse are possible over the next several years. As of 2024, no further news has been released relating to hair research.
Tsuji/Riken – Multiplied hair follicle primordiums or “germs” is the therapeutic focus of Dr. Takashi Tsuji at the Riken Institute. Dr. Tsuji’s method of hair cloning involves taking a hair follicle tissue sample from a patient and multiplying specific cells in culture to create an unlimited amount of hair follicle germs which can be transplanted back into a patient’s scalp. Dr. Tsuji has announced that he is still seeking funding to enter a clinical trial as of Summer 2021. As of 2024, Dr Tsuji has announced that he has restarted OrganTech and they are on track to begin clinical research in 2024, with clinical trials beginning in 2026.
Triple Hair – TH07 is a topical combination formula comprising minoxidil, finasteride, and latanoprost. Triple Hair conducted its own human trial of TH07 in which 100% of trial subjects responded positively and many had dense regrowth, according to the company. The Triple Hair website lists 2022 as a timeframe for a phase 3 clinical trial of TH07. In June 2024, a research article was published in which patients with AGA were treated topically once daily for 6 months with TH07. It has also received approval from the European Medicines Agency to start Phase 3 trials in Europe.
Topadur Pharma – TOP-M119 is a topical small molecule drug that targets the cGMP-enzyme regulation system. It has the potential to enter human trials by 2024. In May 2024, Topadur Pharma AG and Oshen Holdings SA signed an agreement to develop the liquid topical formulation of TOP-M119 for treating alopecia.
Turn Biotechnologies – TRN-001 is an epigenetic reprogramming therapy that utilizes mRNA technology. It is delivered via injection for the purpose of reversing aging and damage to hair follicles. Turn Biotechnologies CEO Anja Krammer told Follicle Thought that her company is moving towards human trials in late 2022. In 2024, TRN-007 is mentioned in the pipeline for hair regrowth and is currently in the in vitro research stage.
Yuva Biosciences – Y100 is a natural botanical compound that stimulates mitochondrial function. Yuva made headlines in 2018 for reversing gray hair and hair loss in mice for the first time through the restoration of mitochondrial function. The company has begun a clinical trial for skin wrinkles in 2021 and have likely started a hair trial by January 2022. According to an early interview given to Follicle Thought, Yuva has intentions to create pharmaceutical as well as over-the-counter products to stimulate hair growth. It recently released its YuvaBio® Y100™ in a topical product as part of a partnership with BosleyMD. They also got 7.5M funding in February 2024
As of November 2024 there are an astounding 51 companies listed, with some of them containing multiple treatments in their pipelines. Things can only get better from here.
Looking for more information on any of these companies or key terms? Start with the search function built into this website! There are likely multiple references to each of these companies in previous Follicle Thought articles.
Thanks to all of our faithful supporters on https://www.patreon.com/FollicleThought for your appreciated contributions to this website.
It would be super helpful if you could list which of these are available today as research chemicals. For instance, I believe Breezula can be purchased as a research chemical already, right? Is this the case with other peptide therapies listed, such as KY19382?
Thank you for the suggestion Jay. At this time I don’t have plans to include that info, but it’s always a possibility. There’s not an easy way to verify the authenticity/integrity of every manufacturer that claims to have these chemicals.
Thanks so much for your comprehensive coverage of hair loss treatments in the pipeline. I always look forward to receiving your updates! I appreciate all that you do to keep us apprised of developments in the field.
You’re welcome Bob, thanks.
Very nice admin. This page is excellent.
I am most excited about Kintor and possibly TechnoDerma, CK Region. I also hope that Pelage/Allergan and Cassiopea provide updates soon.
Everything they have grown so far its infinite budgets and endless clinical trials, 2021, and I still haven’t seen the efficient technology which made hairs grow…
Thanks Admin….I don’t see Mane Biotech on the list. Are they history?
Same deal with Mane Biotech, they don’t want to be in an article until they say so.
Great work,
Thank you for sharing this.
Fantastic idea, thanks for the overview. Could you include that list into your existing Excel-spreadsheet with mechanism of action, web-link, trial-timeline, link to your last article,…and put that as a permanent link into your menu like „updates“?
Don‘t want to be impudent though, it’s just a suggestion.
You forgot to include HanBio and Yokohama/Fukuda in your list.
Thanks for the reminder on Han and Fukuda! Will add them asap. Any others that people know please share.
Oh go cry me a river @arnd. Go study medicine/biochemistry then and find a treatment, I am so sure you will do better. Also Kintor is really promising.
Thanks blave. Yes, arnd’s comment had to be removed as it was just troll material.
And thanks to john doe for the tips on companies over the months!
Thank you admin for the information you share with us. For me the best forum about hair loss. Please continue like this :-))))))))
Yuva bioscience left
Thanks for the suggestion. I’m undecided about companies who are creating natural over the counter topicals and Yuva fits that category. I think I’ll wait until more data comes.
I loved the list. My son sent me a link to Nutrafol. Site had photos of increased hair growth. Have you heard of them and if so, what is your opinion.
I’ve heard of Nutrafol of course, but have never taken it. My opinion is that it may be a support to a regimen, and it’s a pretty good formula as far as natural supplements go, but I would not have high expectations in terms of regrowth on its own. You’d have to weigh whether you want to try it for a few months and can spare the $ depending on what type of result you get, etc. Like most things.
What about omega therapeutics and olix pharma?
Olix is listed, sorry.
Thanks admin!
Yes, Omega thanks!
Absolutely brilliant reporting here, Administrator !
I’m looking forward mostly to hopemedicine phase 2 results as well and KY . I believe that the genetic approaches will be very effective as well and of course stemson tx . Other than that, I don’t see any of these making a big impact
Bonjour, je suis à la recherche d’un produit pour alopécie aréata, suite à la maladie de Lyme et sa cohorte; ces produits topiques existent: où peut-on les acheter? Merci pour une réponse.
Cordialement.
Hi Andre, you should speak to a dermatologist about JAK inhibitors or other options for areata.
Drug approval agencies(FDA) are very strange organizations
They approve the drug for Covid without research
And they are very strict in approving medications for alopecia
These two things are very different.
The vaccine for Covid is playing with the genetic code
And alopecia is an aesthetic problem
Who’s crazy here???
I hear where you’re coming from ah, but that one time situation is too weird of an occurrence to compare to. On the bright side, I remember hearing recently in some interview that the 21st Century Cures Act has helped certain types of anti-aging gene therapies move into clinical trials faster. The regulations aren’t the biggest hurdle in my opinion, we need multi-millionaires to step to the plate and put ~$10M towards hair regrowth tech. That could change things for a few companies/startups! Honestly, I’m waiting for a couple of super rich guys with hair loss to get together to make it happen. In the event that a new treatment is created it becomes one of the most lucrative business decisions ever.
ah: Just to be clear: “the genetic code” implies that the Covid vaccines somehow interfere with the human genetic code by gene editing or altering DNA. This is complete and utter nonsense; and potentially dangerous as it can put people off getting a life saving vaccine. If anyone doubts that then please don’t rely on some Twitter feed, or wacko blog you happend to read; instead try reading some science . There are more than enough journals e.g. Scientific American, and New Scientist which explain exactly how the vaccines work (whether they be the more traditional sort like AZ, or the newer mRNA ones e.g. Pfizer). PS the huge efforts put into getting the vaccines approved by the likes of the FDA is hardly a surprise when you have a pandemic with large numbers of deaths and the whole World economy suffering. Much as we would all dearly love to see a cure for hair loss, it hardly compares (!!)
It can be a domino effect
If they can without research
We can too
Hi Admin, thanks! 40 companies in the list and there are so many more to add. The pure number of companies is impressive and we will see a lot in the next months.
What about
Applied Biology
Giulliani
Cure Bio TX
Aranda
And treatments like
Hemp Oil, CBD
Cold Plasma Devices
Exosomes
Thanks John! I had thought of AB, and thought that their research doesn’t really fit because I forgot about their microbiome therapy to metabolize scalp DHT, I will add them. I’m not big on adding Giuliani because their work is in over the counter topicals and I wasn’t impressed with their roll out of the WAY-316606 based product. will add Cure Bio! Aranda’s website is not specific enough just yet. Hemp is a natural OTC and really a long shot to have any effect; Which was the company doing a real pipeline exosome product for hair? By the way unapproved exosomes have been banned by the FDA recently! https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
Thanks Admin. Looking forward to updates.
Admin, you should make an article on 3HSD theory developed by joaopassos4444. He has a discord and the results beat any of these companies. There are guys regrowing like hell, I advise you to check it out. If you want I can share a link for discord if he doesn’t mind.
Cheers,
Thanks, I’d be willing to make a low key article page for people to share their photos like I’m doing with RIZN and OstriGrow.
Sure, that would be great if others could see their work. They are fine with adding new members and more people willing to participate.
https://discord.com/invite/QvawKgJSgm
They have a few very good results simply using broccoli sprouts as topical and/or oral intake. The hassle is they have to grow broccoli sprouts daily or freeze them, but well worth it since there aren’t any supplements or products with enough concentration.
When are real big players finally entering the game? I am sick and tired of staring at amateur companies like Cassiopea, Replicel, Follica, Hair clone or Histogen. I can see from a mile that their products are a joke.
HairClone is an interesting potential therapy in my opinion. https://folliclethought.com/aderans-hair-cell-injection-results/
Crazy, i am already suffering for a bit less than ten years and waiting for a cure. I am sure that at least a couple of billions is already invested but until now everything we have and get are more and more different approaches, most of them don’t even pass phase 2… Crazy how far other reaseach areas have gone in the meantime with far smaller investments. Crazy, that it is so difficult to provide us normal, just normal life quality… I still hope this changes in the near future
I would be surprised if the amount invested lifetime into clinical hair cures is even $100M. I’d imagine it’s in that ballpark, certainly not billions.
Could you please share the link? I have heard they are using sulforophane and already have lots of people with very good results and without any side effects. Could you at least elaborate on what they are doing or how it works? I’ve been following at reddit but they only use discord now.
This was the latest post at reddit, but since they only discuss at discord apparently, for anyone interested:
https://www.reddit.com/r/tressless/comments/osb15i/the_theory_that_explains_everything_first/
Please share link for the page where all are posting updates on Rizn.
Thank you ..
https://folliclethought.com/rizn-before-after-photos-plus-discussion/
When in doubt an internet search using the keyword you’re looking for + Follicle Thought will always work too ?
Thank you Admin,
I did try that it is listing FT linkedin page but not this website page.
I will give one more try.
Thanks. There is no Linkedin FT page, at least that I’ve created, but perhaps you mean RIZN Linkedin page. I try searching on private browsing window “RIZN Follicle Thought” and it comes up first response.
Bingo..
“RIZN Follicle Thought” gives me as first response.
“rizn follicle thought” (lower case) give article page and your twitter page.
My bad it is twitter page (https://mobile.twitter.com/folliclethought?lang=en) not linked-in
I’m surprised that the Rizn artivle wouldn’t show up in the first page of results when searching with lower case letters, but no big deal either way.
Great work admin, appreciate your effort .
Thank you Shayak.
If I use kintors product and the AR receptors are destroyed will they come back after not continuing treatment? Or is it a cure?
I assume you’re talking about the GT20029 AR degrader. I believe the receptors would become functional after discontinuing treatment, but I’ve not heard Kintor offer any explanation about that type of situation before.
Omega Therapeutics is founded by the same scientist that founded Moderna and developed the first vaccine for Covid. Pretty good credentials, was happy to see them involved in hair loss. Interesting article on the company in last weeks Barrons.
What do you think of Arbor Labs?
Too early to tell. All natural topical with limited data. Worth observing though.
https://rizn.ca/shop-rizn/?utm_source=Newletter&utm_medium=Shop+Button&utm_campaign=code_TH16_expires_soon_EN Is the product effective in the treatment of baldness in men?
Please advise before purchasing
Ahmed, please bring the discussion to this thread https://folliclethought.com/rizn-before-after-photos-plus-discussion/ Thank you. The product has some theoretical merit, there were some photos shared of TH16 in this article https://folliclethought.com/new-company-triple-hair-topical/ however, it’s new and it is an all natural product. It also depends on where your expectations are at.
Ahmed if it’s not approved by countries regulatory agency like the FDA than it probably not going to be effective………
Woofy97
Thank you
Beautiful work FT. And keep up the hope gentlemen and ladies.
Are there certain trials or treatments from the exhaustive master list that may be considered more major or significant? I would love to read about them first before checking out the other ones.
George, thanks. Just as this article states, please check the Ultimate Guide to Hair Regeneration article for a more focused look at frontrunners and “fan favorites.”
Hi admin.
Congratulations on the great job you do.
I have 2 questions, the first is how long do you think there could be an effective cure for baldness?
The second is if you know of any company that is researching a cure for gray hair, luckily I have hair but my gray hair started to appear very young and it is something that makes me very complex.
Thank you Jorge. An effective cure for baldness could take anywhere from 6-15 years, I really don’t think it could take longer than that. Or, there is miracle chances that something could come in the next 6 years in a territory that allows fast commercialization that no one was expecting, perhaps not a full cure, but a marked improvement on current treatments. Life provides potentials.
Yes, for hair repigmentation please read the description for Eirion Therapeutics.
Hi Admin,
The rizn article – is that dead? You haven’t recieved any feedback or pics from users than the one’s commenting?
I leave it open for the people to share their feedback or to link their photos. RIZN is a very new product still…
Everything can be bought
Brezula have on aliexpress
I saw on one forum that several people purchased the KX-826
Whether that works or not
I do not know
Hi admin, any new article coming before the end of the year?
Shayak, yes certainly. I hope to have a new interview with an interesting company within a week or two.
@FT is this a new company or an old company making some progress?
It’s a known company. Hope to have it out this week.
Ohh that’s great! Keep up the good work admin.
Alphabet (google) and deepmind have founded a research company together. They want to develop drugs and therapies with the help of AI. In addition, model approaches to accelerate drug development. Probably nothing against hair loss now, but still great news. Deepmind and Google are number 1 when it comes to AI. Could cure many diseases
https://www.cnet.com/news/alphabet-launches-isomorphic-labs-an-ai-driven-drug-discovery-startup/
https://www.isomorphiclabs.com/blog
There is a new company in Germany named MalliaBioTech. They are working on a topical hair loss treatment based on CD83 molecule.
Prof. Steinkasserer was actually researching for proteins to treat MS. They were surprised when they found out that the protein induced hair growth in mice. The animals got a 3 times higher hair density and further research showed that they even created brand new hair follicles. Right now they are in the lab testing if CD83 is working in the human system. If they get the same positive effect of it, clinical trails might start in 4 to 5 years.
Maybe 4 to 5 years is more on the conservative side. I think chances are good that it’d start sooner if they get positive results since the bavarian state is funding them.
https://www.fau.de/2021/10/news/wissenschaft/fau-projekt-gewinnt-foerderung-fuer-mittel-gegen-hormonell-bedingten-haarausfall/
https://www.youtube.com/watch?v=6i3eHhpxwW0
Thank you for sharing and also please consider bookmarking the Updates page which has brief updates usually on a weekly basis, like this MalliaBioTech news for example. https://folliclethought.com/updates/
Yuva bio taking OTC route, good news?
we need something good sooner ,next generation treatments for next generation we have to hand over the mantle anyway any update from device companies? Don’t want name names No data from either of them .
Is Yoda reading ? Thanks admin
Hi Admin, I just saw that you didn‘t list „Inscobee“. Maybe you have a reason for that.
I think they are legit and deserve a spot.
Kind regards
Thanks Ben! I was not really aware of them (forgot), I will add them soon.
Admin, did you have any contact with HairClone, because the release datum on the pipeline was just changed to 2022?
Please see update from 8/18/21, and like I get used to saying here “Please keep an eye on the Updates page, consider bookmarking it, and stay up to date with all updates several times a week.”
Unreal that nothing ever works as planned/promised, delays and sketchiness are the rule, not an exception here. Its quite crazy, also the whole Verteporfin situation, I am wondering if this will ever be trialed for human hair transplants and I do not think it will 😀 This is why we need Kintor, they are the only competent company around imo
I hear ya blave, also, sometimes things just don’t make it in honest clinical trials like setipiprant, follicum, HST001, SM04554. At least there are legitimate trials being made.
Thanks. Yeah you’re right. 🙂 I honestly think that the whole research/treatment development really started improving in the last 10 years. 10 years ago, the (only) hope was in things like Intercytex and Aderans. Now we have Hairclone, so it is already tied. But Hairclone isn’t by far the most promising today imo. But we have a topical anti-androgen which passed a phase 2 trial which did not happen since RU. Moreover, there are definetely promising things like Hope Medicine, which might turn out to be a full-blown cure, and the company developing it has a lot of funding. Quite a few treatments should start clinical trials in the next 2 years, hopefully really promising ones like UK and KY might start within the next 2-3 years. Of course there are also companies working on hair cloning like Stemson, J Hewitt, Koehler Lab and Dr. Tsuji, but in my personal opinion even if the concepts work, we wont see them applied to customers in 15 years. But what is here today which wasn’t really 10 years ago is evidence that Dermarolling works and some data on topical finasteride being as effective as oral without so much dht inhibition in the plasma. If you compare it to 5 years ago,
Some news about Almirall’s Finjuve topical finasteride on the Updates page and more news on different subject coming tomorrow.
I will give topical finasteride (Almirall Finjuve) a shot if it is available for purchase in EU. I had bad sides on oral, but believe topical with the correct vehicle *may* be a tolerable alternative. I believe that modified finasteride/dutasteride are our best bet until topical AR-antagonists become available.
I tried to see if you had mentioned unthin in any of your posts, but didn’t seem so.
Does this have any merits?
https://unthin.co.uk/
It appears to be topical finasteride and minoxidil, which are more or less the gold standard of pharmaceutical treatment for hair loss, so if everything is as it seems then yes. I’m just unfamiliar with the regulations in the UK for this sort of thing, it appears you only need to fill out a questionnaire to receive the product. In the US there is a necessary online consultation with a licensed MD before receiving topical finasteride. Someone from the UK may be more familiar. But in any event it appears that topical finasteride is not so hard to come by in the EU.
Hey admin, I have a wild idea for you and your widely respected by the hair loss community and hair loss researchers
Tsuji got clearance to start trials in Japan on humans in june, stemson has an amazing research team and is backed by big pharma. a friend of mine emailed Kyocera and said they already developed the manufacturing technology, but did not release it because organ technologies went bankrupt. I could give you the email to the vp who said that. Why don’t you try to get kyocera, stemson and tsuji to work together to speed up the development and introduce everybody to each other. I feel like everybody has their own piece and it could expedite trials from lets say 2029 to 2025.
stemson has the ip, tsuji gives them the trial pathway, and Kyocera partners to lend out their manufacturing technology.
In my humble opinion trials are everything. we’re not mice so the sooner we know if this technology works on humans the better.
Yeah man. Stemson/Koehler/Tsuji/Kyocera/Hair clone vs hair loss. This would be the final fight.
I like the Spirit of your idea, Edward. I’m just not sure if such companies would be willing to work together, and mores so I’m not sure if these 3 companies really have much in common. Stemson has the wherewithal to get something going in Japan if they feel the time is right. I know that Kyocera developed some technology which would suit Dr. Tsuji’s efforts, it’s not clear if the devices would be suited for Stemson as well. To reiterate, Stemson’s and Tsuji’s approaches are different. I’m sure that Stemson has already raised much more capital than Organ Technologies, so I wouldn’t worry about them. We would all like the human trials to start sooner and so far the greatest catalyst for human trials is money. Stemson, Tsuji, everyone, they could use more money, spread the word.
Carmell Therapeutics added to the list. They are working on a type of product which can be described as similar to “off the shelf” PRP.
Thanks to john doe for the find. The other companies mentioned will be added to the list soon.
Just received the new interview responses, article will be up in a few days.
Winlevi is not available in the U.S.
https://www.empr.com/home/news/acne-vulgaris-treatment-winlevi-now-available/
Hi,
I came across this study by harvard.
https://www.nature.com/articles/s41586-021-03417-2
They say it could cure hair loss.
Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China
a safer and more effective drug is in urgent need to address the concerns for the people suffering from hair loss. As a topical AR antagonist with an identified target, KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA male patients. We look forward to further expanding the clinical potential of KX-826 and benefiting more people suffering from hair loss.”
What products of this list can is aviable in 2 or 3 years
Possibly HairClone and Kintor Pharmaceuticals pyrilutamide
The promising treatment is cloning, but it has not yet been tested on humans. It is unclear whether it can replace Cassiopea and kintor finasteride. While there are so many bald people in the world, there are 42 companies, right?
Hi admin, thanks so much for all this great work.
How close are we? What are your top cloning / hair regeneration companies and who’s closest to a human clinical trial? I read a few months ago on here that there was a company that was going into human trials in late 2021.
I really appreciate all research and interviews you do!
Thanks Greg! Check Ultimate Guide article.
Just want to mention a medical article for those who were waiting on minoxiboost from applied biology (upregulating sulfotransferase enzyme to convert minoxidil into minoxidil sulphate): Sulfation of minoxidol by human liver phenol sulfotransferase (https://scholar.google.com/scholar_lookup?title=Sulfation%20of%20minoxidol%20by%20human%20liver%20phenol%20sulfotransferase&author=C.%20N.%20Falany%20&author=E.%20A.%20Kerl&publication_year=1990). So apparently rather than bother with minoxiboost or tretinoin shampoo, we should just be using minoxidil orally so that the liver’s sulfotransferase enzyme can convert it.
Thanks for this resource. Is there a way to sort it by most recent update rather than alphabetically?
Smill, I’m going to keep the list alphabetical. For a list of more timely therapies in development please visit the Ultimate Guide to Hair Regeneration article. There are some therapies in this post’s list which could have an update in a year from now or tomorrow, no way to really tell, but the Ultimate Guide companies are all on a development track with a few exceptions of companies who have a long way to go but have good public communications.
[…] Thought has mentioned TDM-105795 in its previous alopecia research pipeline summaries, here and here. It’s always encouraging to see the advancement of a novel therapeutic candidate for […]